Digital and Biomarker‐Based Monitoring for Schizophrenia‐Treatment Adherence
Samuel Inshutiyimana, Kush Rajeshbhai Rana, Michael Matiop Aleu, Naomi Bwalya, Bonaventure Nsengimana, Onesmas Kipkurui · 2026
Read Digital and Biomarker‐Based Monitoring for Schizophrenia‐Treatment Adherence by Samuel Inshutiyimana, Kush Rajeshbhai Rana, Michael Matiop Aleu, Naomi Bwalya, Bonaventure Nsengimana, Onesmas Kipkurui (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13387042.txt.
Description
Inshutiyimana and five co-authors review digital and biomarker monitoring for schizophrenia treatment adherence in a 2026 paper. Nearly half of patients do not take antipsychotic drugs as prescribed. Missed doses can lead to relapse, hospital stays, and worse quality of life.
Digital pills can detect intake with very high accuracy. Watches and other wearables track sleep, heart signals, and activity that hint at lapses or early relapse. Lab markers, including aptamer tests in body fluids, can confirm drug presence with care. Artificial intelligence may merge these streams to forecast lapses. The authors note ethical, cost, and system barriers that joint work must solve.
Catalog record
| CREATOR | Samuel Inshutiyimana, Kush Rajeshbhai Rana, Michael Matiop Aleu, Naomi Bwalya, Bonaventure Nsengimana, Onesmas Kipkurui |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |